Ironwood Pharmaceuticals Inc - Asset Resilience Ratio
Ironwood Pharmaceuticals Inc (IRWD) has an Asset Resilience Ratio of 4.76% as of September 2018. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check Ironwood Pharmaceuticals Inc strategic capital allocation to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2007–2018)
This chart shows how Ironwood Pharmaceuticals Inc's Asset Resilience Ratio has changed over time. See net asset quality index of Ironwood Pharmaceuticals Inc to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Ironwood Pharmaceuticals Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see IRWD company net worth.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $19.84 Million | 4.76% |
| Total Liquid Assets | $19.84 Million | 4.76% |
Asset Resilience Insights
- Limited Liquidity: Ironwood Pharmaceuticals Inc maintains only 4.76% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Ironwood Pharmaceuticals Inc Industry Peers by Asset Resilience Ratio
Compare Ironwood Pharmaceuticals Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2 |
Drug Manufacturers - Specialty & Generic | 0.20% |
|
Huadong Medicine Co Ltd
SHE:000963 |
Drug Manufacturers - Specialty & Generic | 0.05% |
|
Tianjin Chase Sun Pharmaceutical Co Ltd
SHE:300026 |
Drug Manufacturers - Specialty & Generic | -0.89% |
|
Walvax BioTech
SHE:300142 |
Drug Manufacturers - Specialty & Generic | 2.20% |
|
Guangdong Zhongsheng Pharmaceutical Co Ltd
SHE:002317 |
Drug Manufacturers - Specialty & Generic | 6.62% |
|
Fujian Cosunter Pharmaceutical Co Ltd
SHE:300436 |
Drug Manufacturers - Specialty & Generic | -2.56% |
|
Celltrion Pharm Inc
KQ:068760 |
Drug Manufacturers - Specialty & Generic | 12.49% |
|
Hunan Warrant Pharmaceutical Co. Ltd. A
SHG:688799 |
Drug Manufacturers - Specialty & Generic | 0.40% |
Annual Asset Resilience Ratio for Ironwood Pharmaceuticals Inc (2007–2018)
The table below shows the annual Asset Resilience Ratio data for Ironwood Pharmaceuticals Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2018-12-31 | 0.00% | $0.00 | $332.05 Million | -- |
| 2017-12-31 | 15.80% | $95.68 Million | $605.67 Million | -19.59pp |
| 2016-12-31 | 35.39% | $251.21 Million | $709.82 Million | +6.62pp |
| 2015-12-31 | 28.77% | $178.11 Million | $619.12 Million | -23.42pp |
| 2014-12-31 | 52.18% | $174.04 Million | $333.51 Million | +8.41pp |
| 2013-12-31 | 43.77% | $122.11 Million | $278.96 Million | +30.06pp |
| 2012-12-31 | 13.71% | $31.53 Million | $229.91 Million | -23.01pp |
| 2011-12-31 | 36.72% | $76.73 Million | $208.98 Million | -30.88pp |
| 2010-12-31 | 67.59% | $203.71 Million | $301.37 Million | +51.93pp |
| 2008-12-31 | 15.67% | $22.05 Million | $140.72 Million | -6.05pp |
| 2007-12-31 | 21.71% | $29.51 Million | $135.91 Million | -- |
About Ironwood Pharmaceuticals Inc
Ironwood Pharmaceuticals, Inc., a biotechnology company, focuses on the development and commercialization of therapies for gastrointestinal (GI) and rare diseases in the United States and internationally. It sells linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation, as well … Read more